Activity Report 2023–2025
The clinical and research activity of the Pediatric Hematology and Oncology Unit reflects sustained growth in volume, clinical complexity, and development of clinical trials, consolidating its role as a reference center in pediatric oncology.
Activity Summary 2023–2025
148
Phase I–II trials opened
(START CIOCC structure)
803
Patients enrolled
in Phase I–II trials
127
Initial consultations
(2023–2025)
132
Second opinions
(national and international)
Clinical Trial Activity
START Pediatrics Activity (Phase I–II)
- Active trials: 4 pediatric trials (0–18 years) and 2 trials including patients aged 12–99 years.
- Patients recruited: 5.
- Screening failures: 2.
START CIOCC Activity (Reference Structure)
The HM START Pediatrics Unit is part of the START CIOCC structure. Over the past three years, 148 Phase I–II clinical trials have been opened, with a total of 803 patients enrolled.
Phase III Trials
- Active trials: 3.
- Patients recruited: 10.
Phase IV Trials
- Active trials: 2.
- Patients recruited: 5.
Clinical Activity
2023
- Initial consultations: 36.
- Second opinions (national and international): 38.
2024
- Initial consultations: 46.
- Second opinions (national and international): 43.
2025
- Initial consultations: 45.
- Second opinions (national and international): 51.
Outlook 2026
The HM START Pediatrics Unit was inaugurated in October 2025. Following the implementation of a professional clinical trial management program, projections for 2026 estimate a doubling of current trial numbers and patient enrollment.